New Diagnostics for Gliomas


Orphan designation for Tetrofosmin

The consortium is pleased to announce that, on 14/10/2016 the European Commission has granted to proACTINA SA, Orphan Designation for tetrofosmin for the diagnosis of Glioma, following positive opinion by EMA. The product is registered in the “Community register of orphan medicinal products” with an EU orphan designation number: EU/3/16/1764.

This achievement has been one of the major milestones in GLIOMARK project.

See here the related press release.

Project GLIOMARK has started

The European Commission, within the frames of Horizon 2020-SME-Instrument-Phase 2 (PHC-12), has positively evaluated the project "GLIOMARK" and approved funding of €4.7 million for the next 4 years. Objective of "GLIOMARK" is to clinically validate the permeability of the blood brain barrier (BBB) as an in vivo biomarker for the diagnosis of gliomas. This will be accomplished by means of the radiotracer 99mTc-tetrofosmin (TTF) and the imaging technique Single-Photon Emission Computer Tomography (SPECT). The project will be coordinated by ConsulTech GmbH (Germany) and implemented in close collaboration with ProActina SA (Greece).